Earnings
GSK Says 'No Read Across' From HIV Prevention Shot Analysis To Treatment Version
Analysts pressed GSK's executives on its four-monthly HIV prevention shot; they held the line and offered few details.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Analysts pressed GSK's executives on its four-monthly HIV prevention shot; they held the line and offered few details.
Earnings
Luke Miels told analysts GSK will flag problems openly, as questions on HIV injectables dominated the third-quarter call.
Earnings
CEO Sam Sledge says the company is "turning away opportunities" but will limit capital spending to replacing and refurbishing its fleet.
Earnings
Executives say talks on several hundred megawatts are down to two active deals, with deployment at scale possible as early as late 2027.
Markets
The Jeep and Ram maker held its 2026 outlook and its 2027 free cash flow target, with adjusted operating income of €256 million.
Earnings
The gas producer is holding back about nine wells and calls 2027 a year of transition, betting on 13 Bcf a day of new demand by 2028.
Earnings
Danny Brown says a deal must carry synergies the company is confident it can capture, as Expand also guides to $80 million of marketing EBITDA.
Earnings
Kevin Holleran pointed to dealer conversions and an installed base worth over 85% of sales while new pool permits slip.
Earnings
The pool-equipment maker's outlook implies fourth-quarter sales flat to up 3%, with volume the swing factor.
Earnings
Dana raised its 2026 sales outlook but kept adjusted EBITDA at about $825 million, citing cost inflation and delayed customer recoveries.
Earnings
Timing of the decision is "fluid," Dana's finance chief said, after the company raised its 2026 buyback target to $469 million.
Markets
The White House's seafood strategy pairs five partners' pledges with a list of foreign practices the trade office says hurt U.S. fishermen.